Skip to main content

Table 2 The baseline laboratory parameters in the nonsevere group and severe group of COVID-19 and normal controls

From: The potential role of serum angiotensin-converting enzyme in coronavirus disease 2019

Variables

Normal controls (n = 60)

Nonsevere group (n = 120)

Severe group (n = 16)

P value

Fibrinogen (mg/dl)

368.00 (290.70–401.00)

430.50 (361.50–549.25)&

574.15 (405.30–668.00)&#

< 0.001

Platelet count (× 109/L)

223.00 (190.25–258.75)

206.50 (165.00–262.50)&

155.00 (125.75–206.00)&#

0.001

WBC count (×109/L)

5.70 (4.90–6.70)

5.05 (4.20–6.80)

5.35 (4.13–7.53)

0.068

Neutrophil% (%)

57.95 (53.08–61.68)

66.50 (59.15–73.48)&

75.70 (64.53–88.98)&#

< 0.001

Lymphocyte% (%)

33.30 (28.65–38.98)

24.45 (18.93–32.08)&

17.45 (8.23–22.25)&#

< 0.001

NLR

1.65 (1.35–2.16)

2.74 (1.88–3.87)&

4.24 (3.00–10.87)&#

< 0.001

Neutrophil count (×109/L)

3.28 (2.57–4.09)

3.30 (2.55–4.39)

3.89 (2.25–6.57)

0.539

Lymphocyte count (×109/L)

1.88 (1.58–2.16)

1.23 (0.9–1.59)&

0.74 (0.47–1.18)&#

< 0.001

Sialic acid (mg/dl)

56.50 (52.85–62.08)

75.90 (67.8–85.95)&

85.75 (82.68–97.38)&#

< 0.001

C-reactive protein (mg/L)

0.67 (0.36–1.71)

7.71 (1.73–26.59)&

36.64 (15.33–69.94)&#

< 0.001

Erythrocyte sedimentation rate (mm/h) a

/

66.00 (38.00–90.75)

89.00 (60.5–105.75)

0.071

Angiotensin-converting enzyme (U/L)

75.00 (57.75–98.50)

63.50 (51.50–75.75)&

49.00 (37.25–67.50)&#

< 0.001

  1. Data are presented as medians and inter-quartile ranges
  2. P values indicate the comparison among nonsevere group, severe group and normal controls
  3. COVID-19 coronavirus disease 2019, WBC white blood cell, NLR neutrophil-to-lymphocyte ratio
  4. &P < 0.05 versus normal control, #P < 0.05 versus nonsevere group
  5. aThe number of COVID-19 patients who tested erythrocyte sedimentation rate was 114 and 12 in the nonsevere and severe group, respectively, and it was not tested in normal controls